drugset / Trial / NCT04882540

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

NCT04882540

Phase 1 Completed 12 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.

Timeline

Start
2021-05-19
Primary completion
2021-06-08
Completion
2021-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 100 mg Oral

Indications

No indication recorded.